Lauren Dong

Lauren Dong

Auto-generated profile, based on publicly available information

Lauren Dong

Weill Cornell Medicine 1 New York, NY

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CWChien-Huan Weng
Chien-Huan Weng
AAAnais Assouvie
Anais Assouvie
LDLauren Dong
Lauren Dong
JBJean-Christophe Beltra
Jean-Christophe Beltra
SBSadna Budhu
Sadna Budhu
TMTaha Merghoub
Taha Merghoub

17 June 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
MEK inhibitors (MEKi) have shown limited success as a treatment for MAPK/ERK pathway–dependent cancers due to various resistance mechanisms tumor cells can employ. CH5126766 (CKI27) is an inhibitor that binds to MEK and prevents release of RAF, reducing the relief of negative feedback commonly observed with other MEKis. We observed that CKI27 increased MHC expression in tumor cells and improved T cell–mediated killing. Yet, CKI27 also decreased T-cell proliferation, activation, and cytolytic activity by inhibiting the MAPK/ERK pathway that is activated downstream of T-cell receptor signaling. Therefore, we aimed to balance the positive and negative immunomodulatory effects of MEKis for optimal combination with immunotherapy. Intermittent administration of CKI27 allowed T cells to partially recover and costimulation via GITR and OX-40 agonist antibodies completely alleviated inhibition of function. In Kras mutant lung and colon tumor mouse models, intermittent CKI27 and anti-GITR significantly decreased tumor growth and prolonged survival when further combined with CTLA-4 immune checkpoint blockade. Moreover, this triple combination increased CD8+ and CD4+ T-cell proliferation, activation, and effector/memory subsets in the tumor-draining lymph nodes and tumors and led to intratumoral regulatory T-cell destabilization. These data, collectively, will allow for more informed decisions when optimizing combination regimens by overcoming resistance, reducing toxicity, and generating long-term immune responses.

15 September 2026
Verified
Other
Open access
MGMariam Mathew George
Mariam Mathew George
LHLinda Hamadene
Linda Hamadene
YMYacine Marouf
Yacine Marouf
NCNicholas Ceglia
Nicholas Ceglia
DHDaniel Hirschhorn
Daniel Hirschhorn
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 7 | CTX+αPD-1+αCTLA-4 does not change entropy of TIL populations

15 September 2026
Verified
Other
Open access
MGMariam Mathew George
Mariam Mathew George
LHLinda Hamadene
Linda Hamadene
YMYacine Marouf
Yacine Marouf
NCNicholas Ceglia
Nicholas Ceglia
DHDaniel Hirschhorn
Daniel Hirschhorn
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 6 | CTX+αPD-1+ αCTLA-4 treatment does not affect myeloid cells

17 June 2026
Verified
Other
Open access
PDF file
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 2. MEK inhibition with CKI27 increases MHC and checkpoint ligand expression. Murine tumor cell lines were treated with DMSO or CKI27 for 72 hr and either with or without IFNγ (5ng/mL) for the last 24hr; n=3. FACS analysis of representative histograms for the MFI of MHC-I (H2Kb/Kd and H2Db/Dd), MHC-II, PD-L1, CD80 and CD86 are shown.

17 June 2026
Verified
Other
Open access
PDF file
LDLauren Dong
Lauren Dong
HCHyejin Choi
Hyejin Choi
SBSadna Budhu
Sadna Budhu
ISIsabell Schulze
Isabell Schulze
SVSvena Verma
Svena Verma
TMTaha Merghoub
Taha Merghoub
Supplementary Figure 10. The triple combination reduces tumor growth, is T cell dependent, and protects from re-challenge in LLC and CT26. (A-D) LLC tumor bearing mice were treated with vehicle, isotypes, GITR, CTLA-4, 5mg/kg 4on/3off CKI27, and/or CD8 for 4 weeks and tumor growth was monitored over time. (A) Average tumor growth (volume, mm3) of immunocompetent mice. (B) Average tumor growth (volume, mm3) of immunodeficient mice. (C) Average tumor growth (volume, mm3) of CD8 depleted mice. (D) Average tumor growth (volume, mm3) of mice from (A) that were re-challenged. (E-H) CT26 tumor bearing mice were treated with vehicle, isotypes, GITR, αCTLA-4, 2mg/kg 4on/3off CKI27, and/or αCD8 for 4 weeks and tumor growth was monitored over time. (E) Average tumor growth (volume, mm3) of immunocompetent mice. (F) Average tumor growth (volume, mm3) of immunodeficient mice. (G) Average tumor growth (volume, mm3) of CD8 depleted mice. (H) Average tumor growth (volume, mm3) of mice from (E) that were re-challenged. Two-way ANOVA test with Bonferroni’s correction for multiple comparisons was used. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).